In these cases, neoadjuvant endocrine therapy (NET) has demonstrated promising clinical response rates in HR+ HER2– breast cancer and may enhance breast conservation eligibility while minimizing the need for extensive axillary surgery and avoiding systemic toxicity associated with chemotherapy. This evidence concerns the gene ERBB2 and breast cancer.